AMLX - Balance Sheet - Amylyx Pharmaceuticals, Inc.

Current Liabilities	28.4 M
Accounts Payable	2.94 M
Short-Term Debt	1.52 M
Other Current Liabilities	23.9 M
Non-Current Liabilities	463 K
Long-Term Debt	0
Other Non-Current Liabilities	463 K

Millions

	Dec-2024	Dec-2023	Dec-2022	Dec-2021	Dec-2020	Dec-2019
ASSETS
Cash & Cash Equivalents	77.4	170.2	62.5	50.2	12.9	3.1
Short Term Investments	99.1	201.2	284.4	45.9	0	0
Receivables	0.4	40.0	15.3	0	0	0
Inventory	0	38.3	9.8	0	0	0
Other Current Assets	12.5	14.9	10.1	8.8	0.8	0.1
Total Current Assets	189.4	464.7	382.1	101.5	13.6	3.2
PP&E	2.7	6.4	8.1	0.5	0.2	0
Intangible Assets	0	0	0	0	0	0
Goodwill	0	0	0	0	0	0
Long Term Investments	0	0	0.7	0.2	0.2	0
Other Long Term Assets	1.5	46.4	0.5	3.4	0.1	18 K
Other Assets	0	0	1	1	1	0
Total Assets	193.6	517.5	391.5	105.6	14.1	3.2
LIABILITIES
Accounts Payable	2.9	22.1	6.3	4.4	3.6	2.2
Short Term Debt	1.5	2.3	4.1	0	0	0
Other Current Liabilities	23.9	57.7	36.3	13.0	3.7	2.3
Total Current Liabilities	28.4	82.0	46.6	17.4	7.3	4.5
Long Term Debt	0	2.0	4.2	0	1.4	14.9
Deferred Tax Income	0	0	0	0	0	0
Other Liabilities	0	0	0	35 K	72.1	9.1
Total Liabilities	28.9	84.0	50.8	256.8	80.8	28.6
EQUITY
Common Stock	7 K	7 K	7 K	1 K	1 K	1 K
Retained Earnings	(606.7)	(304.9)	(354.2)	(155.8)	(67.9)	(25.6)
Other Accumulative Comprehensive Income/Loss	92 K	0.2	86 K	9 K	(72.1)	(7.7)
Total Equity	164.8	433.4	340.6	(151.2)	(66.7)	(25.4)
Total Liabilities and Equity	193.6	517.5	391.5	105.6	14.1	3.2
SHARES OUTSTANDING
Common Shares Outstanding	68.1	67.2	66.5	57.9	56.5	56.5

Free